Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access program of pimitespib in advanced gastrointestinal stromal tumor
jRCT2031210526Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of pimitespib in gastrointestinal stromal tumor (GIST), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Adverse events and adverse drug reactions, Vital signs and laboratory abnormalities and 1 more. Started Feb 2022; status: completed.
02
Drugs
pimitespib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on jRCT2031210526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210526.